Related Experiment Videos
Prevention of Rh-hemolytic disease
Journal of the National Medical Association
|July 1, 1977
Summary
Anti (D) immunoglobulin (RhoGAM) therapy effectively prevented Rh-isoimmunization in Rh-negative mothers delivering Rh-positive infants. This prophylaxis is crucial due to the risk of Rh-isoimmunization in unprotected women.
Area of Science:
- Immunology
- Obstetrics
- Perinatology
Background:
- Rh-isoimmunization poses a significant risk to Rh-negative mothers carrying Rh-positive fetuses.
- Previous studies indicate a risk of antibody development in unprotected Rh-negative women.
Purpose of the Study:
- To evaluate the efficacy of Anti (D) immunoglobulin (RhoGAM) in preventing Rh-isoimmunization.
- To assess the incidence of Rh-isoimmunization in a cohort of Rh-negative women post-delivery.
Main Methods:
- A study involving 25 Rh-negative women who received Anti (D) immunoglobulin therapy after delivery of Rh-positive infants.
- Comparison with a control group of 51 unprotected Rh-negative patients.
Main Results:
- None of the 25 treated patients showed evidence of Rh-isoimmunization.
- Two out of 51 (approximately 3.9%) unprotected patients developed detectable antibodies.
Conclusions:
- Anti (D) immunoglobulin (RhoGAM) prophylaxis is highly effective in preventing Rh-isoimmunization.
- Given the potential risks, RhoGAM prophylaxis is strongly advocated for Rh-negative women.
- The low incidence of Rh-negative patients in the study environment does not diminish the importance of prophylaxis.